Regulating the Madness – Drugs, Mental Health, and the Trump Administration

The regulators have been busy. While a recent wave of PBM reforms cracking down on price transparency reporting requirements and spread pricing has in many ways upended the pharmaceutical industry, the Department of Labor (DOL) also just intensified efforts to enforce non-quantitative treatment limitation (NQTL) requirements for mental health parity compliance. Amidst this whirlwind of regulatory changes, TPAs, brokers, and plan sponsors have been scrambling to keep up—all while bracing for the impending renewal season. Join The Phia Group’s webinar to gain invaluable insights into compliance best practices as well as new regulatory reforms that may be coming your way.